Roles of MA Modification in Oral Cancer (Review)

Overview

Journal Int J Oncol

Specialty Oncology

Date 2022 Nov 16

PMID 36382642

Authors

Huimin Liu

Yinyu Wang

Tianyi Xue

Zhijing Yang

Shaoning Kan

Ming Hao

Yang Gao

Dongxu Wang

Weiwei Liu

Affiliations

Soon will be listed here.

Abstract

Oral cancer is one of the highly malignant tumors with poor prognosis. The pathogenic mechanisms of oral cancer have remained to be fully elucidated and this brings significant challenges to the treatment. RNA modification is a common intracellular chemical modification that has been related to various pathological processes, such as blood diseases, immune system diseases and cancer. As the most common and abundant RNA modification in eukaryotic mRNA, N‑methyladenosine (mA) modification has a crucial role in several cancers, including oral cancer. mA modification directly affects gene expression levels and regulates various physiological and pathological processes. It has been demonstrated that mA modification may affect the proliferation, migration and invasion of oral cancer cells by regulating the level of mA modification. In the present review, the effects of mA modification on the proliferation and death of oral cancer cells, as well as the occurrence and development of oral cancer, were analyzed in order to provide a new target for treatment. Furthermore, the roles of mA modification in chemotherapy resistance and potential immunotherapy were analyzed and new treatment ideas were provided.

Citing Articles

N6-methyladenosine RNA modification in head and neck squamous cell carcinoma (HNSCC): current status and future insights.

Janakiraman P, Jayaprakash J, Muralidharan S, Narayan K, Khandelia P Med Oncol. 2024; 42(1):12.

PMID: 39580759 DOI: 10.1007/s12032-024-02566-4.

Role of N‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review).

Pan J, Tong F, Ren N, Ren L, Yang Y, Gao F Oncol Rep. 2024; 51(6).

PMID: 38757383 PMC: 11110010. DOI: 10.3892/or.2024.8747.

Lenvatinib resistance mechanism and potential ways to conquer.

Bo W, Chen Y Front Pharmacol. 2023; 14:1153991.

PMID: 37153782 PMC: 10157404. DOI: 10.3389/fphar.2023.1153991.

References

Wang P, Doxtader K, Nam Y . Structural Basis for Cooperative Function of Mettl3 and Mettl14 Methyltransferases. Mol Cell. 2016; 63(2):306-317. PMC: 4958592. DOI: 10.1016/j.molcel.2016.05.041. View

Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L . A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2013; 10(2):93-5. PMC: 3911877. DOI: 10.1038/nchembio.1432. View

Alarcon C, Lee H, Goodarzi H, Halberg N, Tavazoie S . N6-methyladenosine marks primary microRNAs for processing. Nature. 2015; 519(7544):482-5. PMC: 4475635. DOI: 10.1038/nature14281. View

Sheng H, Li Z, Su S, Sun W, Zhang X, Li L . YTH domain family 2 promotes lung cancer cell growth by facilitating 6-phosphogluconate dehydrogenase mRNA translation. Carcinogenesis. 2019; 41(5):541-550. DOI: 10.1093/carcin/bgz152. View

Chai A, Lim K, Cheong S . Translational genomics and recent advances in oral squamous cell carcinoma. Semin Cancer Biol. 2019; 61:71-83. DOI: 10.1016/j.semcancer.2019.09.011. View

Zhang P, He Q, Lei Y, Li Y, Wen X, Hong M . mA-mediated ZNF750 repression facilitates nasopharyngeal carcinoma progression. Cell Death Dis. 2018; 9(12):1169. PMC: 6281568. DOI: 10.1038/s41419-018-1224-3. View

Hsu P, Zhu Y, Ma H, Guo Y, Shi X, Liu Y . Ythdc2 is an N-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Res. 2017; 27(9):1115-1127. PMC: 5587856. DOI: 10.1038/cr.2017.99. View

Chen Y, Gibson S . Three dimensions of autophagy in regulating tumor growth: cell survival/death, cell proliferation, and tumor dormancy. Biochim Biophys Acta Mol Basis Dis. 2021; 1867(12):166265. DOI: 10.1016/j.bbadis.2021.166265. View

Shu C, Weng J, Chang H, Liu P, Chen J, Peng C . Tribulus terrestris fruit extract inhibits autophagic flux to diminish cell proliferation and metastatic characteristics of oral cancer cells. Environ Toxicol. 2021; 36(6):1173-1180. DOI: 10.1002/tox.23116. View

10.

Bonasio R, Tu S, Reinberg D . Molecular signals of epigenetic states. Science. 2010; 330(6004):612-6. PMC: 3772643. DOI: 10.1126/science.1191078. View

11.

Yu D, Pan M, Li Y, Lu T, Wang Z, Liu C . RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic metastasis and epithelial-mesenchymal transition of head and neck squamous carcinoma cells via stabilizing slug mRNA in an m6A-dependent manner. J Exp Clin Cancer Res. 2022; 41(1):6. PMC: 8722037. DOI: 10.1186/s13046-021-02212-1. View

12.

Visvanathan A, Patil V, Arora A, Hegde A, Arivazhagan A, Santosh V . Essential role of METTL3-mediated mA modification in glioma stem-like cells maintenance and radioresistance. Oncogene. 2017; 37(4):522-533. DOI: 10.1038/onc.2017.351. View

13.

Wang J, Qiao Y, Sun M, Sun H, Xie F, Chang H . FTO promotes colorectal cancer progression and chemotherapy resistance via demethylating G6PD/PARP1. Clin Transl Med. 2022; 12(3):e772. PMC: 8926902. DOI: 10.1002/ctm2.772. View

14.

Han H, Fan G, Song S, Jiang Y, Qian C, Zhang W . piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL. Blood. 2020; 137(12):1603-1614. DOI: 10.1182/blood.2019003764. View

15.

Shi H, Wei J, He C . Where, When, and How: Context-Dependent Functions of RNA Methylation Writers, Readers, and Erasers. Mol Cell. 2019; 74(4):640-650. PMC: 6527355. DOI: 10.1016/j.molcel.2019.04.025. View

16.

Lan H, Liu Y, Liu J, Wang X, Guan Z, Du J . Tumor-Associated Macrophages Promote Oxaliplatin Resistance METTL3-Mediated mA of TRAF5 and Necroptosis in Colorectal Cancer. Mol Pharm. 2021; 18(3):1026-1037. DOI: 10.1021/acs.molpharmaceut.0c00961. View

17.

Zhu F, Yang T, Yao M, Shen T, Fang C . HNRNPA2B1, as a mA Reader, Promotes Tumorigenesis and Metastasis of Oral Squamous Cell Carcinoma. Front Oncol. 2021; 11:716921. PMC: 8494978. DOI: 10.3389/fonc.2021.716921. View

18.

Liu Z, Zhong J, Zeng J, Duan X, Lu J, Sun X . Characterization of the m6A-Associated Tumor Immune Microenvironment in Prostate Cancer to Aid Immunotherapy. Front Immunol. 2021; 12:735170. PMC: 8438522. DOI: 10.3389/fimmu.2021.735170. View

19.

Pastushenko I, Blanpain C . EMT Transition States during Tumor Progression and Metastasis. Trends Cell Biol. 2018; 29(3):212-226. DOI: 10.1016/j.tcb.2018.12.001. View

20.

Wang Y, Zhu G, Tian D, Zhou C, Li N, Feng Y . Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer. BMC Cancer. 2022; 22(1):316. PMC: 8943990. DOI: 10.1186/s12885-022-09377-8. View